Skip to main content
SpringerLink
Log in

Treatment overview

  • Chapter
  • First Online:
Handbook of Lymphoma

Abstract

In recent years, advances in the understanding of the biology of the lymphomas together with the development of new effective treatments have resulted in significant improvements in the outcomes for most common lymphoma subtypes. A definitive cure is the goal for patients with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, anaplastic large T-cell lymphoma, in addition to most subtypes of lymphoma when presented in a localized stage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22-32.

    Google Scholar 

  2. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.

    Google Scholar 

  3. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857-877.

    Google Scholar 

  4. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non- Hodgkin’ s lymphomas. Hematol Oncol. 2005;23:10–17.

    Google Scholar 

  5. Fruehauf S, Seggewiss R. It’s moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol. 2003;122:360-375.

    Google Scholar 

  6. van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:977-982.

    Google Scholar 

  7. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:4201-4205.

    Google Scholar 

  8. Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMTLymphoma Working Party. Haematologica. 2013;98:1014-1021.

    Google Scholar 

  9. Robinson S, Dreger P, Caballero D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464-473.

    Google Scholar 

  10. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:426-432.

    Google Scholar 

  11. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de infomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310-317.

    Google Scholar 

  12. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540-1545.

    Google Scholar 

  13. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-1054.

    Google Scholar 

  14. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065-2071.

    Google Scholar 

  15. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190.

    Google Scholar 

  16. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677-2684.

    Google Scholar 

  17. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.

    Google Scholar 

  18. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007:233-242.

    Google Scholar 

  19. Bander NH, Czuczman MS, Younes A. Antibody-drug conjugate technology development for hematologic disorders. Clin Adv Hematol Oncol. 2012;10:1-16.

    Google Scholar 

  20. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311-319.

    Google Scholar 

  21. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520-525.

    Google Scholar 

  22. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944-953.

    Google Scholar 

  23. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688-3695.

    Google Scholar 

  24. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N Engl J Med. 2013;369:507-516.

    Google Scholar 

  25. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008-1018.

    Google Scholar 

  26. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.

    Google Scholar 

  27. Intlekofer AM, Younes A. Precision therapy for lymphoma–current state and future directions. Nat Rev Clin Oncol. 2014;11:585-596.

    Google Scholar 

  28. Batlevi CL, Horwitz S, Moskowitz CH, et al. Targeted genomic sequencing prospectively identifies clinically relevant genetic alterations across lymphoma subtypes. Hematol Oncol. 2015;33:100-180.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

    Anastasios Stathis

Authors
  1. Anastasios Stathis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Stathis, A. (2016). Treatment overview. In: Younes, A. (eds) Handbook of Lymphoma. Adis, Cham. https://doi.org/10.1007/978-3-319-08467-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08467-1_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08466-4

  • Online ISBN: 978-3-319-08467-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation